Teva announces U.S. FDA has approved AJOVY for preventive treatment

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced that the U.S. Food and Drug Administration, FDA, has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide, CGRP, antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine.